| mRNA |
Erlotinib |
CCLE |
pan-cancer |
AAC |
-0.12 |
0.008 |
| mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.098 |
0.008 |
| mRNA |
AKT inhibitor VIII |
GDSC1000 |
pan-cancer |
AAC |
-0.091 |
0.008 |
| mRNA |
AZD0530 |
CTRPv2 |
pan-cancer |
AAC |
-0.095 |
0.008 |
| mRNA |
Nutlin-3 |
CTRPv2 |
pan-cancer |
AAC |
-0.09 |
0.008 |
| mRNA |
WZ4002 |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.008 |
| mRNA |
canertinib |
CTRPv2 |
pan-cancer |
AAC |
-0.094 |
0.009 |
| mRNA |
Nutlin-3a (-) |
GDSC1000 |
pan-cancer |
AAC |
-0.088 |
0.009 |
| mRNA |
AZD6482 |
GDSC1000 |
pan-cancer |
AAC |
-0.083 |
0.009 |
| mRNA |
vorinostat:carboplatin (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.087 |
0.009 |